Viz.ai and Addario Lung Cancer Medical Institute Forge Partnership to Enhance Lung Cancer Care Through AI
In a significant development aimed at revolutionising lung cancer care, Viz.ai, a leader in artificial intelligence-powered disease detection and intelligent care coordination, has partnered with the Addario Lung Cancer Medical Institute (ALCMI). This global consortium includes 25 premier lung cancer research institutions from around the world. The collaboration, announced recently, aims to utilise AI for precision medicine and early detection, ultimately aspiring to improve lung cancer patient outcomes.
Viz.ai's sophisticated AI algorithms, currently employed in 1,700 hospitals and health systems across the United States and Europe, will be at the forefront of this partnership. These algorithms enhance healthcare outcomes by providing timely and precise insights, assisting healthcare providers in expediting diagnoses and coordinating care through advanced machine learning techniques.
The partnership's dual objectives focus on optimising treatment plans with AI-powered tools and expediting clinical workflows, particularly in the nodule workup process. This collaboration promises to leverage AI to streamline healthcare provider efforts, ensuring timely intervention and coordinated care for lung cancer patients.
The collaboration brings together Viz.ai's cutting-edge technology and ALCMI's extensive expertise in patient engagement and research. ALCMI’s innovative approach to lung cancer research and patient involvement complements Viz.ai's technological prowess, making the partnership a poised endeavour to set new standards in lung cancer care.
Chris Mansi, MD, CEO and Co-Founder of Viz.ai, expressed his enthusiasm for the new collaboration, stating, "We are pleased to partner with ALCMI to improve the standard of care for lung cancer patients." His sentiments reflect the broader mission of the partnership to harness the power of AI in healthcare, aiming for timely detection and efficient care coordination to better manage lung cancer treatment processes.
As lung cancer remains one of the leading causes of cancer-related deaths worldwide, advancements in technology and clinical practices are crucial. The Viz.ai and ALCMI partnership highlights a progressive approach toward integrating AI with clinical workflows, promising to deliver more personalised and effective treatments, ultimately enhancing the quality of life for lung cancer patients globally.
Source: Noah Wire Services